Know Cancer

forgot password

FTPC (Focal Therapy for Prostate Cancer): A Pilot Study Using Focal Low Dose Rate Brachytherapy as an Alternative to Active Surveillance and Radical Treatment for Favourable Risk Prostate Cancer.

18 Years
Not Enrolling
Prostate Cancer

Thank you

Trial Information

FTPC (Focal Therapy for Prostate Cancer): A Pilot Study Using Focal Low Dose Rate Brachytherapy as an Alternative to Active Surveillance and Radical Treatment for Favourable Risk Prostate Cancer.

1. Purpose

To test the efficacy, acute side effects and long term safety of Focal Therapy in
Prostate Cancer, as compared to conventional radical lose dose radiation prostate
brachytherapy (LDR-PB).

2. Hypothesis

We hypothesize that, in an appropriately selected group of early-stage, favourable risk
prostate cancer patients, focal LDR-PB will lead to fewer acute side effects, long term
complications resulting is a better quality of life than radical LDR-PB.

We also hypothesize that multi-modal, multi-parametric imaging will enable monitoring
of the results of focal therapy with an accuracy that is high enough to eventually
replace repeated (and invasive) mapping biopsies.

3. Justification

The imaging study we propose is unique in terms of its multi-modality, multi-parametric
approach. Local disease will be monitored by a very complete set of multi-parametric
MR, ultrasound and PET-CT imaging. Potential spread of the disease may be captured by
abdominal and whole-body PET-CT. Comparison with biopsies will be more accurate than in
other studies because biopsy location will be accurately provided by the trans-perineal
three-dimensional template-guided pathological mapping biopsy (TTMB), in contrast to
Post-radical prostatectomy (RP) studies that use axial whole mount slices which suffer
from a significant change in prostate physical shape and unpredictable deformation due
to fixation, making an accurate registration of pathology and imaging difficult.

The impact of our study on the field of medical imaging will also be significant.
Advances in the topics of deformable multi-modal registration, dosimetry, and the
characterization of cancer as image features in MR, ultrasound and PET-CT are expected.
These findings will be widely disseminated in papers addressing both clinical and
technical publications.

We are not aware of any study in which TTMB-guided focal brachytherapy has been
implemented and tested. A center of our size, with our record in outcomes, and with a
complete set of imaging expertise and tools to help with patient selection and
monitoring, may make a very significant impact in how focal therapy can be implemented
and evaluated. Therefore, we have the potential to provide valuable input on how to
translate focal therapy into standard care for appropriately selected patients.

4. Objectives

The specific objectives of this study are:

1. To develop provisional criteria for what constitutes focal disease and treatment
plans appropriate for focal LDR-PB.

2. To show that patients undergoing focal therapy have a better quality of life than
those undergoing radical therapy.

3. To correlate multi-modal, multi-parametric imaging results with the results of
mapping biopsies with the goal of developing image-based techniques for patient
selection and monitoring.

5. Research Method

Participants in the study will undergo multi-modal, multi-parametric imaging as
outlined in the study protocol (MRI, Ultrasound imaging, and PET/CT). Participants that
are eligible to continue in the study and receive focal therapy will undergo 3D-
Template-Guided Trans-Perineal Pathological Mapping Biopsy (TTMB). Participants will
also be asked to complete study surveys and have repeat pathological mapping done at 2
year post treatment..

6. Statistical Analysis

In our recruiting plan, we have assumed that approximately 50% of the participants who are
initially eligible will continue to focal therapy. The planned sample size for this pilot
study is 10.

Imaging hypotheses: The hypothesis that focal treatment will change the imaged treated area
tissue properties but will leave unchanged properties of tissue in the untreated area will
be tested using paired data on each participant.

Inclusion Criteria:

- Must be 18 years of age or older

- Must be able to give informed consent

- Histologic diagnosis of prostate adenocarcinoma made on transrectal guided prostate
biopsy with no fewer than 6 cores taken

- The prostate cancer is considered suitable for a strategy of active surveillance as
well as conventional radical treatment.

- No more than 2 cores from one lobe containing cancer

- Gleason sum no greater than 3+4 =7 in any one core

- Clinical T stage no higher than T2a

- Serum prostate-specific antigen (PSA) no higher than 10 ng/mL

- No previous radiation therapy to the pelvis

- No prior history of malignancy except non-melanoma skin cancer

- Must be suitable for general or spinal anesthesia

- Must not be on coumadin or other anticoagulants

- Must be suitable for multi-parametric MRI scan (excluded are those with significant
renal impairment that would preclude the use of contrast agents and may exclude some
patients with cardiac pacemaker, wires, or defibrillator; artificial heart valve;
brain aneurysm clip; electrical stimulator for nerves or bones; ear or eye implant;
implanted drug infusion pump; coil, catheter, or filter in any blood vessel. Some men
with metallic prostheses; shrapnel, bullets, or other metal fragments retained in the
body may be excluded as well.

Exclusion Criteria:

- They are unable to participate in an MRI scan.

- They are unable to undergo general or spinal anesthesia.

- They are on anticoagulation therapy (blood thinners).

- They have had previous radiotherapy to the pelvis.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Outcome Measure:

Constitute Disease Criteria and Appropriate Treatment Plans

Outcome Description:

To develop criteria for what constitutes focal disease and treatment plans appropriate for focal LDRB.

Outcome Time Frame:

Approximately 4 years; upon study completion

Safety Issue:


Principal Investigator

William J Morris, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

British Columbia Cancer Agency


Canada: Health Canada

Study ID:




Start Date:

May 2013

Completion Date:

May 2017

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms